Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D03DJL
|
|||
Former ID |
DCL000846
|
|||
Drug Name |
Indacaterol
|
|||
Synonyms |
312753-06-3; QAB149; Arcapta; Onbrez; QAB-149; QAB 149; UNII-8OR09251MQ; 753498-25-8; CHEMBL1095777; CHEBI:68575; 8OR09251MQ; (R)-5-(2-(5,6-diethyl-2,3-dihydro-1H-inden-2-ylamino)-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one; 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one; Indacaterol Maleic Acid Salt; Indacaterol (USAN/INN); Indacaterol [USAN:INN:BAN]; 5-{(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl}-8-hydroxyquinolin-2(1H)-one; QAB-149; 5-(2-(5,6-Diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1H-quinolin-2-one; Indacaterol/mometasone
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J44, J44.9] | Approved | [1], [2] | |
Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Phase 4 | [3] | ||
Company |
Novartis
|
|||
Structure |
Download2D MOL |
|||
Formula |
C24H28N2O3
|
|||
Canonical SMILES |
CCC1=C(C=C2CC(CC2=C1)NCC(C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC
|
|||
InChI |
1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1
|
|||
InChIKey |
QZZUEBNBZAPZLX-QFIPXVFZSA-N
|
|||
CAS Number |
CAS 312753-06-3
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
14805326, 15126362, 17194957, 43529924, 50944939, 96025998, 103751149, 104152520, 114788160, 126665799, 134339311, 135252041, 136946521, 137248550, 137261964, 140383548, 144116077, 152258566, 152343993, 160645865, 160647401, 162011653, 162197410, 164227489, 164777215, 172919100, 174528841, 175266645, 175426936, 187051758, 189561508, 198991946, 223601296, 223667503, 223701040, 224342928, 226432041, 241382349, 246478537, 247088325, 251916861, 251918100, 252063646, 252110200, 252436254
|
|||
ChEBI ID |
CHEBI:68575
|
|||
ADReCS Drug ID | BADD_D01147 ; BADD_D01148 | |||
SuperDrug ATC ID |
R03AC18
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Adrenergic receptor beta-2 (ADRB2) | Target Info | Agonist | [4], [5] |
KEGG Pathway | Calcium signaling pathway | |||
cGMP-PKG signaling pathway | ||||
cAMP signaling pathway | ||||
Neuroactive ligand-receptor interaction | ||||
Endocytosis | ||||
Adrenergic signaling in cardiomyocytes | ||||
Salivary secretion | ||||
NetPath Pathway | TCR Signaling Pathway | |||
Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
Beta2 adrenergic receptor signaling pathway | ||||
Pathway Interaction Database | Arf6 trafficking events | |||
Arf6 signaling events | ||||
Reactome | Adrenoceptors | |||
G alpha (s) signalling events | ||||
WikiPathways | Monoamine GPCRs | |||
Calcium Regulation in the Cardiac Cell | ||||
GPCRs, Class A Rhodopsin-like | ||||
Vitamin D Receptor Pathway | ||||
GPCR ligand binding | ||||
GPCR downstream signaling | ||||
GPCRs, Other |
References | Top | |||
---|---|---|---|---|
REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7455). | |||
REF 2 | 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. | |||
REF 3 | ClinicalTrials.gov (NCT00442351) Efficacy and Tolerability of Maintenance Treatment With Asmanex Twisthaler Versus Placebo in Mild/Moderate Persistent Asthmatics (Study P04654)(TERMINATED). U.S. National Institutes of Health. | |||
REF 4 | Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94. | |||
REF 5 | Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.